Innogenetics is an international biopharmaceutical company working in the areas of specialty diagnostics and therapeutic vaccines.

Its Diagnostics Division develops a large number of specialty products
covering three areas: infectious diseases (including hepatitis C, hepatitis B and HIV), genetic testing (HLA tissue typing, cystic fibrosis and innate immunity) and neurodegeneration (Alzheimer's disease). In its Therapeutics Division, Innogenetics focuses on the development of therapeutic vaccines to address unmet medical needs in the field of infectious diseases, with two compounds now in clinical trials (hepatitis C in phase 2 and hepatitis B in phase 1).

Innogenetics' headquarters are in Gent, Belgium, with sales affiliates in the United States, Germany, France, Spain, and Italy. Innogenetics employs 570 people worldwide and has a market capitalization of approximately EUR400 million.

By combining Innogenetics' expertise in developing and marketing specialty diagnostics and PamGene's advanced technology platform, multiparameter assays will be developed and updated rapidly, thus reducing their time-to-market. Innogenetics is currently developing the PamStation#12, for testing up to 400 parameters in one sample run.

Innogenetics